Results 211 to 220 of about 36,022 (296)

Gastric Emptying in Obesity and Weight‐Loss Interventions: Physiology, Assessment, and Clinical Implications

Comprehensive Physiology, Volume 16, Issue 5, October 2026.
Obesity is associated with accelerated gastric emptying. Weight‐loss interventions each impose a distinct emptying signature: acceleration after sleeve gastrectomy and gastric bypass, delay after endoscopic sleeve gastroplasty, intragastric balloon, and GLP‐1 receptor agonists.
Maxime Amoyel, Rachida Lebtahi, Tigran Poghosyan, Maude Le Gall, Heithem Soliman   +4 more
wiley   +1 more source

Correction: Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists. [PDF]

Cardiovasc Toxicol
Khatami S, Faghihi M, Tavakoli G, Szmit S, Yousefifard M.   +4 more
europepmc   +1 more source

GIP Regimen [PDF]

, 2020
openaire   +1 more source

Endoscopic small bowel therapies for type 2 diabetes

Nutrition in Clinical Practice, Volume 41, Issue 5, Page 1296-1306, October 2026.
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel, Zehra Naseem, Prisha Gattu, Stephen Firkins, Roberto Simons‐Linares   +4 more
wiley   +1 more source

GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer's and Parkinson's disease. [PDF]

Front Neurosci
Hölscher C.
europepmc   +1 more source

GIP is back

Cahiers de Nutrition et de Diététique
Bernard Portha, Junjun Liu
openaire   +1 more source

GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation. [PDF]

Curr Psychiatry Rep
Schifano F, De Luca MA, Bonaccorso S, Arillotta D, Floresta G, Martinotti G, Papanti GD, Corkery JM, Chiappini S, Guirguis A.   +9 more
europepmc   +1 more source

Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

Nutrition in Clinical Practice, Volume 41, Issue 5, Page 1318-1333, October 2026.
Abstract Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause of discontinuation ...
Vikash Singhani, Muhammad Ehsan, Sara Valencia, Ahmed Nadeem, Eisha Moazzam, Winfield Scott Butsch, Samita Garg   +6 more
wiley   +1 more source

Specific Collagen Peptides Support Postprandial Metabolic Health by Modulating Incretin Hormones, Gastric Transit, and Glycemic Control in Participants with Normoglycemia and Prediabetes. [PDF]

Curr Dev Nutr
Virgilio N, Schön C, Steiner N, Schlageter V, Wilhelm M, Silva CI, Gevaert E, Prawitt J.   +7 more
europepmc   +1 more source

Real‐World Outcomes of Telemedicine Shared Medical Appointments in Obesity Management

Obesity Science &Practice, Volume 12, Issue 5, October 2026.
ABSTRACT Introduction Shared Medical Appointments (SMAs) have recently emerged as a novel tool in weight management as they are efficient, bypass logistic barriers to physical attendance, decrease attrition, and are cost‐effective. This study aimed to observe outcomes among patients enrolled in an insurance‐based weight loss program, called Program for
Keerthana Haridas, Jeffrey Wei, Lei Lei, Derek Pham, Nicholas Jackson, Na Shen   +5 more
wiley   +1 more source